Effect of teriparatide on vertebral fracture risk factors in osteoporosis patients .
This report has been verified
by one or more authors of the
original publication.
Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide
Curr Med Res Opin. 2014 May;30(5):931-6237 elderly men and postmenopausal women, between the ages of 65 and 91 years old, with primary osteoporosis with up to 5 prevalent vertebral fractures caused by low BMD of the lumbar spine, were randomly assigned into 1 of 2 groups, a treatment and a placebo, to determine the effect a once a week administration of 56.6 microgram teriparatide had on bone mineral density and bone turnover markers 72 weeks after intervention. The results of the study indicated that percentage change in lumbar bone mineral density was significantly better in the teriparatide group when compared to the placebo treatment. One incident of vertebral fracture occurred in the teriparatide group compared to 16 in the placebo group. The percentage of treatment effect that could be explained by lumbar bone mineral density was 83%, as calculated by Freeman’s method.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
